BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 22035435)

  • 1. Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
    Yazici Y; Regens AL
    Bull NYU Hosp Jt Dis; 2011; 69(3):233-7. PubMed ID: 22035435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinase inhibitors for the treatment of rheumatoid arthritis.
    Yazici Y; Steiger B
    Bull NYU Hosp Jt Dis; 2012; 70(3):204-7. PubMed ID: 23259630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Okamoto H; Kobayashi A
    N Engl J Med; 2011 Jan; 364(1):83-4; author reply 84. PubMed ID: 21208113
    [No Abstract]   [Full Text] [Related]  

  • 4. Healing the Syk through kinase inhibitors.
    Rivera J; Colbert RA
    N Engl J Med; 2010 Sep; 363(14):1362-4. PubMed ID: 20879886
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel small-molecular therapeutics for rheumatoid arthritis.
    Fleischmann R
    Curr Opin Rheumatol; 2012 May; 24(3):335-41. PubMed ID: 22357358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.
    MacFarlane LA; Todd DJ
    Int J Rheum Dis; 2014 May; 17(4):359-68. PubMed ID: 24460872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [JAK inhibitor].
    Yamaoka K; Tanaka Y
    Nihon Rinsho; 2013 Jul; 71(7):1243-7. PubMed ID: 23961674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Otón T; Silva-Fernández L; Andreu JL
    N Engl J Med; 2011 Jan; 364(1):83; author reply 84. PubMed ID: 21208114
    [No Abstract]   [Full Text] [Related]  

  • 9. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
    Boers M
    Arthritis Rheum; 2011 Feb; 63(2):329-30. PubMed ID: 21279987
    [No Abstract]   [Full Text] [Related]  

  • 10. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
    Weinblatt ME; Kavanaugh A; Genovese MC; Musser TK; Grossbard EB; Magilavy DB
    N Engl J Med; 2010 Sep; 363(14):1303-12. PubMed ID: 20879879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The status of fostamatinib in the treatment of rheumatoid arthritis.
    Morales-Torres J
    Expert Rev Clin Immunol; 2012 Sep; 8(7):609-15. PubMed ID: 23078058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
    Yamaoka K; Tanaka Y
    Expert Opin Pharmacother; 2014 Jan; 15(1):103-13. PubMed ID: 24188100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
    Scott DL
    Drugs; 2011 Jun; 71(9):1121-32. PubMed ID: 21711059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy: Spleen tyrosine kinase inhibitors--novel therapies for RA?
    Gómez-Puerta JA; Bosch X
    Nat Rev Rheumatol; 2011 Mar; 7(3):134-6. PubMed ID: 21304505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
    Genovese MC; Kavanaugh A; Weinblatt ME; Peterfy C; DiCarlo J; White ML; O'Brien M; Grossbard EB; Magilavy DB
    Arthritis Rheum; 2011 Feb; 63(2):337-45. PubMed ID: 21279990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
    Sonomoto K; Tanaka Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
    Varisco PA; So A
    Rev Med Suisse; 2014 Jan; 10(414):187-91. PubMed ID: 24624736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
    Cohen SB; Koenig A; Wang L; Kwok K; Mebus CA; Riese R; Fleischmann R
    Clin Exp Rheumatol; 2016; 34(1):32-6. PubMed ID: 26575982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D; O'Dell KM; Bandy JL; Boyce EG
    Ann Pharmacother; 2013 Nov; 47(11):1524-31. PubMed ID: 24285764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malignancy and Janus Kinase Inhibition.
    Sivaraman P; Cohen SB
    Rheum Dis Clin North Am; 2017 Feb; 43(1):79-93. PubMed ID: 27890175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.